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Abstract
Mir-205 plays an important role in epithelial biogenesis and in mammary gland development but its role in cancer still
remains controversial depending on the speciﬁc cellular context and target genes. We have previously reported that
miR-205-5p is upregulated in breast cancer stem cells targeting ERBB pathway and leading to targeted therapy
resistance. Here we show that miR-205-5p regulates tumorigenic properties of breast cancer cells, as well as epithelial
to mesenchymal transition. Silencing this miRNA in breast cancer results in reduced tumor growth and metastatic
spreading in mouse models. Moreover, we show that miR-205-5p knock-down can be obtained with the use of
speciﬁc locked nucleic acids oligonucleotides in vivo suggesting a future potential use of this approach in therapy.
Introduction
Despite advances in breast cancer treatment, metastases
still remain the major cause of patients death due to
therapeutic failure and disease recurrence. It is currently
believed that a subpopulation of cells within the tumor
displaying stem-like properties, such as self renewal and
ability to differentiate, drives tumor progression and
metastasis, and is in general more resistant to therapies,
leading to a worst clinical outcome1–4. These cells have
been indicated as: cancer stem cells (CSCs) or tumor-
initiating cells5.
Breast cancer was the ﬁrst solid tumor in which CSCs
were identiﬁed and characterized by the expression of
speciﬁc surface markers including CD44+, CD24– and
EpCam+6. Breast CSCs (BCSCs) are also characterized by
epithelial–mesenchymal plasticity7 and undergo epithelial
to mesenchymal transition (EMT), as well as mesenchy-
mal to epithelial transition (MET) during the different
stages of metastatic spreading. EMT is a program involved
in tissue morphogenesis induced during embryogenesis
by which epithelial cells take on a mesenchymal pheno-
type, loosing their polarity and acquiring the ability of
motility and invasion. Thanks to EMT and MET cancer
cells can switch from epithelial to mesenchymal states and
vice versa, increasing their ability to invade stromal and
vessel tissues, leading to the formation of secondary
tumors8. In cancer progression, EMT is reactivated and is
promoted by the tumor microenvironment leading to the
induction of several transcription factors like Zeb1 and
Snail and to the activation of intracellular signaling
pathways9 enabling cells to move to new sites, allowing
the formation of metastatic lesions.
Accumulating evidences in the last years support the
involvement of microRNAs in EMT modulation by tar-
geting genes related to EMT machinery10,11. MiRNAs are
small regulatory non-coding RNAs, controlling gene tran-
scription through base pairing with the 3′-untranslated
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regions (3′-UTR) of speciﬁc target mRNAs, leading to the
downregulation of gene expression12. However, miRNAs
activity may change depending on the cellular context and
stimuli, indeed the same gene can be regulated by dif-
ferent miRNAs, thus explaining the dualistic and often
controversial role of miRNAs.
MiR-205, is one of the most studied miRNAs in breast
cancer for its involvement in cellular proliferation,
migration and differentiation and it was deﬁned “angel or
devil” in cancer, acting either as an onco-suppressor or as
an oncogene13. Indeed, miR-205 has been shown to
inhibit EMT in several tumors, targeting Zeb1 and Zeb214
but has also been reported to promote proliferation and
metastasis in other models15,16. We have previously
reported that patient derived BCSCs express high levels of
miR-205-5p compared with more differentiated tumor
cells17. We found that miR-205-5p upregulation controls
CSCs phenotype targeting Her2, p63 and Epidermal
growth factor receptor (EGFR) contributing to targeted
therapy resistance17. Here we further investigate the role
of this miRNA in breast cancer progression and show that
miR205-5p silencing impairs the metastatic potential of
BCSCs in vitro and in vivo modulating EMT program.
Moreover, we show that miR205-5p silencing can be
obtained with the use of speciﬁc locked nucleic acids
(LNA) oligonucleotides in vivo suggesting this approach
as a future potential therapeutic tool.
Results
miR-205-5p regulates the tumorigenic potential of BCSCs
Recently we reported that miR-205-5p is overexpressed
in BCSCs compared with more differentiated cancer cells
and by regulating the expression of different molecules
including p63, participates to sustain a stem-like pheno-
type of breast cancer cells, desensitizing these cells to
targeted therapy17.
To further delineate the contribution of miR-205-5p in
the regulation of BCSCs properties, we investigated if this
miRNA also inﬂuenced their tumorigenic potential. To
this end, we stably knocked down miR-205-5p with short
hairpin RNA (shRNA) lentiviral vectors in two patient-
derived BCSC lines and we examined the effect of miR-
205 silencing on proliferation in vitro. As shown in Fig. 1a,
miR-205 suppression reduced the proliferation of both
BCSCs tested.
Then, in order to efﬁciently silence miR-205 in a way
with potential in vivo applications, we took advantage of
the LNA-phosphorothioate (PS) oligonucleotides tech-
nology. Recently, LNA have been used to inhibit endo-
genous small non-coding RNAs in vitro and in vivo18–20
and therapeutic silencing of disease-associated miRNAs
by LNA antisense oligonucleotide is under investigations
in clinical trials for human cancers, autoimmune and
cardiac disorders21–23.
Thus, we tested the effect of miRCURY LNA anti-miR-
205-5p (LNA-i-miR-205-5p) oligonucleotides in vitro,
treating BCSCs cells with two different molar con-
centrations (40 and 120 pmol). As shown in Fig. 1b (and
Supplementary 1A), LNA-i-miR205-5p reduced miR-205-
5p expression levels at both concentrations used and as
early as 24 h after treatment reaching the maximum effect
of inhibition at 120 pmol of LNA anti-miR-205 after 72 h
of treatment.
To conﬁrm the anti-proliferative effect of miR-205
knock-down, we treated BCSCs with 40 pmol of LNA-i-
miR-205-5p or a scrambled control every 72 h. Figure 1c
(and Supplementary 1B) shows that cell proliferation was
signiﬁcantly reduced after 7 days of treatment. Figure 1d
(and Supplementary 1B) conﬁrms that miR-205 levels are
downregulated after 7 days of culture in treated samples.
The effect on proliferation was paralleled by altered
expression of typical BCSCs surface markers such as
CD44 and its splice variant CD44v624, CD24 and alpha-6-
Integrin (CD49f) evaluated both by quantitative reverse
transcriptase-PCR (qRT-PCR) and ﬂuorescence-activated
cell sorting (FACS) silencing mir-205-5p by shRNA or
LNA. Silencing miR-205-5p by shRNA results in sig-
niﬁcant increase in CD24 levels and decrease of CD49f,
full-length CD44 levels and CD44v6 splice variant, the last
known as a bona ﬁde marker of BCSCs (Figs. 2a, b and
Supplementary 2A-B). Similar results were obtained,
treating BCSCs with LNA-i-mir-205-5p or a scramble
control. FACS analysis in Fig. 3a and qRT-PCR in Fig. 3b
show that LNA-i-miR-205-5p treatment reduced sig-
niﬁcantly the expression of CD44v6 and CD49f both at
mRNA and protein level, whereas CD24 and CD44
expression levels remained unchanged. Moreover, treat-
ment with LNA-i-miR-205-5 results in a 20% reduction of
aldehyde dehydrogenase (ALDH1) activity conﬁrming
reduced stemness (Fig. 3c). Altogether these data, suggest
that reducing mir-205-5p expression, switch CSCs into a
less “aggressive” phenotype.
We then tested the effect of miR-205-5p silencing
in vivo, by injecting these cells subcutaneously into NOD-
SCID-GAMMA (NSG) immune-compromised mice. As
shown in Fig. 4a, miR-205-5p silencing resulted in a
modest but signiﬁcant tumor growth rate reduction, as
well as an increased survival evaluated by sacriﬁcing the
mice when tumors reached a cut off of 1 cm3. Figure 4b
conﬁrms downregulation of miR-205-5p in tumors while
staining of sections for Ki67 shows a lower proliferation
activity in tumors from silenced cells compared with
controls (Fig. 4c).
We then tested the in vivo effect of systemic delivery of
miR-205-5p LNA inhibitor. We subcutaneously injected
NSG mice with BCSCs and the day after we intraper-
itoneally treated mice with six doses (20 mg/kg) of LNA
anti-miR-205 or with a scrambled control. Treatment was
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performed immediately after cells injection as we envisage
the potential use of this LNA in adjuvant setting. Sig-
niﬁcant inhibition of tumor growth was observed after the
last LNA injection (on the 18th experimental day) and
tumor volumes differed signiﬁcantly between control and
treated groups up to 25 days (Fig. 4d), when mice were
Fig. 1 miR-205-5p inhibition impairs BCSCs proliferation in vitro. a Cell proliferation assay, by cell count of Trypan blue-stained cells, of BCSC#1
and BCSC#3 infected with mir-205-5p silencing lentivector (shmiR-205) or with the empty vector (ctr). Data are presented as mean ± SD (ANOVA
analysis) of different experiments (n= 2) each performed in triplicate. b qRT-PCR of miR205-5p expression levels of BCSCs#3 treated with 40 pmol
(left) or 120 pmol (right) of miRCURY LNA miR-205-5p inhibitor (LNA-i-miR-205-5p) or the scrambled control (scr) for 24, 48 and 72 h. Data are
presented as mean ± SD (T-test) of three independent experiments each performed in triplicate. c Cell proliferation assay (cell count) of BCSCs#3
treated every 72 h with 40 pmol of LNA miR-205-5p inhibitor or a scramble control and cultured up to 7 days. Data are presented as mean ± SD
(ANOVA test) of two independent experiments each performed in duplicate. d qRT-PCR of miR-205-5p levels of BCSCs treated as described above
after 7 days of in vitro culture. Data are presented as mean ± SD (T-test) of two independent experiments each performed in triplicate
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Fig. 2 miR-205-5p contributes to control BCSCs surface markers. a mRNA expression levels of miR205-5p, CD24, CD44, CD44v6 and CD49f in
BCSCs #3 infected with miR-205-5p silencing lentivector (shmiR-205-5p) or with the empty vector analyzed by quantitative real-time PCR (qRT-PCR).
Data are presented as mean ± SD with T-test analysis of three independent experiments. b Representative FACS analysis of CD24, CD44 and CD44v6
receptors expression of GFP-positive (infected) BCSC#3 cells infected with miR-205-5p silencing lentivector (shmiR: blue line) or with the empty vector
(ctr: red line) (upper panel). Histograms (lower panel) show the mean ± SD with T-test analysis of the percentage fold over control of receptors
expression in two different experiments
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Fig. 3 (See legend on next page.)
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sacriﬁced. Figure 4e shows that tumors xenograft of mice
treated with miR-205 LNA inhibitor expressed about 50%
less of miR-205-5p and immunohistochemistry analysis
(Fig. 4f) conﬁrmed that tumor xenograft of LNA-i-mir-
205-5p group showed signiﬁcant reduction of
Ki67-positive cells, thus a reduced proliferation rate.
Altogether these results suggest an involvement of miR-
205 in tumor formation and establishment.
miR-205-5p controls BCSCs metastatic potential promoting
EMT
We then investigated if miR-205 also regulated the
invasive potential of BCSCs. To this end, we initially
performed a transwell invasion assay showing that miR-
205 silencing results in a decrease (almost 50%) of the
invasive ability of BCSCs (Fig. 5a). As shown in Fig. 5b this
is also accompanied by reduced expression of EMT rela-
ted genes, such as Twist and Vimentin, both at protein
and mRNA level, whereas the expression level of Slug and
Snail remain unchanged (data not shown) suggesting that
silencing this miR mainly affects the EMT pathway driven
by Twist family and not by the Snail/Slug one.
To further investigate a role of miR-205 in invasion, we
used an experimental metastatic model by injecting
2 × 105 BCSCs infected with shmiR-205 construct or with
an empty vector in the tail vein of NSG immune-
compromised mice. Injection of cancer cells in this
model has been shown to result in the formation of
metastatic lesions in the lung of animals25.
Indeed, after 32 days mice were sacriﬁced and lung
metastasis were counted. Consistently with the reduction
of invasive potential shown in vitro, we observed a sig-
niﬁcant reduction of the number and the size (Fig. 5c) of
lung metastasis. In addition, immunohistochemistry ana-
lysis of lung lesions (Fig. 5d) shows that metastatic lesions
of the miR-205 silenced group have a signiﬁcant reduced
proliferation rate (less Ki67-positive cells).
Treatment with LNA anti-miR-205-5p also reduced the
invasive potential of BCSCs in vitro in both cell lines
tested (Fig. 6a and Supplementary 1C). Moreover, we
checked the expression level of EMT regulator genes
in vitro (Fig. 6b and Supplementary 1D) and ex vivo from
tumor xenograft (Figure Supplementary 1E). LNA-i-miR-
205-5p treatment leads to a reduction trend of Twist and
Vimentin mRNA levels and a signiﬁcant reduction in their
protein levels in line with the results obtained by shmiR-
205-5p. Conversely Zeb1, a direct target of miR-205-5p, as
previously reported, is upregulated upon miR-205-5p
silencing (Supplementary 1F), suggesting as recently
described that EMT transcription factors have non-
redundant functions and are not all activated at the
same time26-28.
Finally, we evaluated the effect of LNA-i-miR-205-5p on
the metastatic potential of BCSCs in vivo using the same
model described above and treating animals with four
doses of LNA-i-miR-205 or a scramble control. At the end
of the experiment (30 days after cells injection), we col-
lected lungs and counted and analyzed the metastasis. As
shown in Fig. 6c, treatment with LNA anti-miR-205-5p
signiﬁcantly reduced the number and the size of lung
metastasis. In addition, metastases of LNA-i-miR-205-5p
treated group showed lower percentage of Ki67-positive
cells (Fig. 6d). All these data conﬁrmed that miR-205
inhibition impairs cell proliferation, motility and invasion
ability.
Discussion
Currently, targeting oncogenic miRNAs represents a
new strategy to overcome human cancer and is widely
recognized that a subpopulation of cancer cells within the
tumor, with stem-like features, plays a pivotal role in
cancer progression and recurrence. We have previously
shown that miR-205-5p is upregulated in BCSCs com-
pared with more differentiated tumor cells, contributing
to sustain a stem-like phenotype, also driving targeted
therapy resistance17. These ﬁndings led us to hypothesize
that miR-205-5p could be involved in tumorigenic and
metastatic potential of BCSCs.
In this study, we silenced mir-205-5p in vitro and
in vivo with either shRNA or LNA PS antisense oligo-
nucleotides, chemically modiﬁed to ensure stability, spe-
ciﬁcity and high binding afﬁnity for the target miRNA.
Our in vitro data show that miR-205-5p knock-down
results in reduced proliferative ability of these cells par-
alleled by a reduced expression of CSC markers such as
CD44v6, CD44 and alpha-6-Integrin. These results pro-
vide additional insights into the role of miR-205 in pro-
moting the expansion of stem cells, as previously
(see ﬁgure on previous page)
Fig. 3 miR-205-5p LNA inhibition reduces the stem-like phenotype of BCSCs. a FACS analysis of CD24, CD44 and CD44v6 expression of BCSCs#3
after 24 h of treatment with 120 pmol of miRCURY LNA miR-205-5p inhibitor (LNA-i-miR-205-5p: blue line) or the scramble control (scr: red line)
(upper panel). Data are presented as mean ± SD with T-test analysis of the percentage fold over control of receptors expression in three different
experiments (lower panel). b Real-time PCR of CD24, CD44, CD44v6 and CD49f receptors of BCSCs#3 treated for 24 h as described above. Data are
presented as mean ± SD with T-test analysis. c Representative FACS analysis of ALDH1 activity of BCSCs after 24 h of treatment with 120 pmol of LNA
miR-205-5p inhibitor or the scramble control using Aldeﬂuor Assay. Histograms (lower panel) show the mean ± SD with T-test analysis of the
percentage fold over control of ALDH activity in two different experiments
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described for the progenitors and stem cells populations
in skin during early development29. Indeed, knocking-out
this miRNA in mice causes neonatal lethality with com-
promised epidermal and hair follicle growth, and impaired
proliferation of basal cells in stratiﬁed epithelium, by
modulating the phosphatidylinositol 3 kinase pathway29.
Thus, our ﬁndings support the hypothesis that in CSCs,
genes involved in normal early development like miR-205
are switched on and upregulated.
Along with others, we have previously shown that miR-
205 regulates EMT targeting Zeb114,17, here we show that
miR-205-5p silencing reduces the invasive ability of
BCSCs, modulating the expression of EMT-associated
genes like Vimentin and Twist. In line with in vitro
results, we show that reduced expression of miR-205
in vivo signiﬁcantly impairs tumor growth and metastasis
formation. Indeed the acute treatment of mice with LNA
anti-miR-based therapy, signiﬁcantly reduces the growth
of the primary tumor, as well as the number and the size
of lung metastasis derived from BCSCs injection. Fur-
thermore, the systemic delivery of LNA anti-miR205
resulted in an effective mir-205 silencing with no major
adverse effect, suggesting the potential safety of this
approach.
Several studies18,30 have reported the efﬁciency of LNA
anti-miR-based therapies and miRNA-based therapeutics
are currently entering clinical trials;31 for instance “Mir-
avirsen”, LNA anti-miR122, is the ﬁrst miRNA-targeted
drug to enter phase II clinical trial for its use against
HCV infection21,32. Thus, the discovery and the devel-
opment of new miRNAs therapeutics, used alone or in
combination with other drugs, against cancer and other
disorders, avoiding off-target effects, still remains the
great challenge of medicine. Our work supports the idea
that LNA anti-miR205 can be possibly used as an adjuvant
therapy, to overcome breast cancer progression and
metastatic spreading. However, caution should be used in
suggesting this approach as miR-205-5p has been shown
to act also as a tumor suppressor in other models and
further work is required to clearly understand this
pathway in order to select patients that might beneﬁt from
this approach.
Materials and methods
BCSCs isolation and culture
BCSCs were isolated collecting human breast cancer
tissues at the Department of Surgical, Oncological and
Stomatological Sciences (University of Palermo, Palermo,
Italy), in accordance with the ethical standards of the
Institutional Committee on Human Experimentation and
their molecular subtypes5. Breast cancer tissues were
digested as previously described6,33 and cells were cul-
tured in ultra-low attachment ﬂasks in a selective medium
(serum-free) supplemented with 10 ng/mL ﬁbroblast
growth factor (βFGF) (Peprotech), 20 ng/mL epidermal
growth factor (EGF) (Peprotech) at 37 °C in a 5% (v/v)
CO2 humidiﬁed chamber. In this culture condition, breast
cancer cells grow as sphere structures with cancer stem-
like properties34. We performed all the experiments with
BCSCs#1 and BCSCs#3 derived, respectively, from tumors
histopathologically classiﬁed as follows: BCSC#1 is an
invasive ductal carcinoma, grading G2, Estrogen Receptor
(ER) 90%, Progesterone Receptor (PR) 60%, Human Epi-
dermal growth Factor Receptor 2 (HER2)/neu 3+ and
ki67 > 10%; BCSC#3 is an invasive ductal carcinoma,
grading G2, ER 80%, PR 80%, HER2/neu 3+ and ki67 >
10%17.
For the authentication of BCSCs was used the short
tandem repeat (STR) system (GlobalFiler STR Kit;
Applied Biosystems) and the ABIPRISM 3130 genetic
analyzer (Applied Biosystems) as previously reported5.
Constructs and LNA microRNA inhibitor
To generate shRNA miR-205 lentivector, we cloned
miR-205-5p into pSIH-H1-copGFP Vector (System Bios-
ciences, CA, USA) as previously described17.
Custom miRCURY LNA microRNA inhibitor in vivo
Ready were designed and purchased from Exiqon
(Denmark) with the following sequences: i-hsa-miR-205-
5p 5′-CCGGTGGAATGAAGG-3′ and Scrambled control
(see ﬁgure on previous page)
Fig. 4 miR-205-5p inhibition compromises tumor growth in vivo. a Tumor volume (left panel) of NSG mice (six mice per group) after
subcutaneous injection of 1 × 105 BCSC#3 control and BCSC#3 infected with miR-205-5p silencing lentivector. Data represent the mean ± SEM
(ANOVA test). Survival curve obtained by sacriﬁcing mice when tumors reached the cut off value of 1 cm3. The survival curves were analyzed by
Mantel–Cox test. b Representative H&E staining (upper) and qRT-PCR of miR-205-5p levels (lower) of tumor xenograft samples of control mice group
(ctr) and of miR-205-5p silenced group (shmiR-205-5p). Data are presented as mean ± SD with T-test analysis. c Representative immunohistochemical
staining of Ki67 expression (upper) of tumors xenograft sections of control and shmiR-205-5p groups; (scale bar: 50 μm); data are presented as
percentage of Ki67-positive cells analyzed with T-test (lower). d Tumor growth of NSG mice (ﬁve per group) after subcutaneous injection of 1 × 105
BCSC#3 and treated with 20 mg/kg LNA anti-miR205-5p or a scramble control twice a week for 3 weeks. Mice were monitored up to 25 days and
then sacriﬁced. Data are shown as mean ± SEM (ANOVA test). e Representative H&E of tumors xenograft from scramble and LNA anti-mir-205-5p
mice groups and expression levels of miR-205-5p of tumor xenograft lysates analyzed by qRT-PCR. Data are presented as mean ± SD with T-test
analysis. f Ki67 staining of tumors xenograft sections of groups treated as described above. Data are presented as percentage of Ki67-positive cells
analyzed with T-test (scale bar: 50 μm)
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5′-ACGTCTATACGCCCA-3′. The oligonucleotides
were High Performance Liquid Chromatography (HPLC)
and Na salt exchanged purity level and had full PS
backbones. They were custom designed to work in human
cells in vitro and in mice xenograft of human breast
cancer.
LNA transfection
miRCURY LNA miR-205-5p inhibitor and the scramble
control were used at concentration of 40 pmol (or 120
pmol where indicated) and the mixture was added directly
to cells seeded into six-well ultra-low attachment plated.
Successful miR205-5p inhibition was evaluated by qRT-
PCR.
Virus generation and infections
Lentiviruses were produced by transient co-transfection
of a three-plasmid expression system in the packaging
293T cells, using the calcium phosphate transfection kit
(Invitrogen, Life Technologies) as previously described17.
Then, BCSCs were infected with viral supernatant as pre-
viously described17 and infection efﬁciency was assessed by
Fig. 5 miR-205-5p regulates invasion ability of BCSCs in vitro and in vivo. a Representative images (upper) of transwell invasion assay (24 h) of
BCSCs#3 infected with miR-205-5p silencing lentivector (shmiR-205-5p) or with the control vector (ctr) stained with crystal violet. Quantitative data are
presented as mean ± SD of percentage of invasion of three independent experiments (lower). b Western blot analysis of Vimentin and Twist protein
levels of BCSCs#3 infected with miR-205-5p silencing lentivector or with the control vector. Actin was used as a loading control (upper panel). qRT-
PCR of Twist and Vimentin mRNA expression levels of BCSCs#3 infected as described above. Data presented as mean ± SD (T-test analysis) of three
independent experiments (lower panel). c Representative H&E staining (upper) of lung metastases of NSG mice (6 per group) after tail vein injection
of 2 × 105 BCSCs #3 infected with miR-205-5p silencing lentivector or with the control vector (scale bar: 400 μm). Mice were monitored up to 35 days
and then sacriﬁced. Graphs show, respectively, the number (bottom left) and the size (bottom right) of lung metastases for each group. Data were
analyzed with T-test. d Representative immunohistochemical staining of Ki67 in lung metastases of NSG mice treated as described above (scale bar:
200 μm). Percentage of Ki67-positive cells are shown in the graph (bottom) analyzed with T-test
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ﬂow cytometry (FACSCanto II Instrument, BD Biosciences)
48 h post-infection evaluating the percentage of Green
Fluorescent Protein GFP-positive cells. Data were analyzed
with CELLQuest software (BD Biosciences).
Real-time PCR
For miRNA detection, RNA was extracted from BCSCs
and from tumors by using miRNeasy Mini Kit (Qiagen,
Germany). Tumors were homogenized by Tissue Ruptor
homogenizer (Qiagen, Germany). RNA (50 ng) was used
for reverse transcription using TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystem by Life
Technologies) with the following stem loop-speciﬁc pri-
mers: miR-205-5p RT: 5′-GTTGGCTCTGGTGCAGGGT
CCGAGGTATTCGCACCAGAGCCAACCAGACT-3′
and U44-RT: 5′-GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACAGTCAGTT-3′
(Ref).
Real-time PCR was performed by using SsoAdvanced
Universal Probe Supermix (Bio-Rad) and Universal Probe
Library, Probe #21 (Roche) using the following primers:
miR-205-5p Fw 5′-GCGGCGGTGTAGTGTTTCCTA-3′
Fig. 6 miR-205-5p LNA inhibitor reduces BCSCs metastasis in vitro and in vivo regulating EMT. a Representative images of transwell invasion
assay of BCSCs#3 after 24-h treatment with 40 pmol LNA anti-miR-205-5p or a scramble control. Quantitative data (bottom) are presented as mean ±
SD of percentage of invasion of two independent experiments each conducted in triplicate, analyzed with T-test. b Western blot analysis of Vimentin
and Twist protein levels of BCSCs#3 after 24 h treatment with 40 pmol LNA anti-miR-205-5p or a scramble control; Actin was used as a loading control
(upper panel). qRT-PCR of Twist, and Vimentin mRNA expression levels of BCSCs#3 treated as described above (lower panel); data are presented as
mean ± SD (T-test analysis) of three independent experiments. c Representative H&E staining (upper) of lung metastasis of NSG mice (four per group)
after tail vein injection with 2 × 105 BCSC#3 and treated with 20 mg/kg LNA-i-miR-205-5p or with LNA scrambled control twice a week for 2 weeks
(scale bar: 400 μm). Mice were sacriﬁced after 30 days. Graphs show the quantiﬁcation of the number (bottom left) and the size (bottom right) of lung
metastasis analyzed with T-test. d Representative immunohistochemical analysis of Ki67 expression of lung metastases of NSG mice treated as
described above (scale bar: 200 μm). Data are presented as percentage of Ki67-positive cells in both mice groups and analyzed with T-test (bottom)
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and universal Reverse primer: 5′-GTGCAGGGTCCG
AGGT-3′. miR-205-5p expression was calculated relative
to U44 snoRNA with the following primer:
5′-GCGGCGGCCTGGATGATGATAG-3′. All qRT-PCR
were performed with an ampliﬁcation protocol as follows:
one cycle of 95 °C for 30 s and 40 cycles of 95 °C for 15 s
and 60 °C for 30 s on CFX96 Touch detection system
(Bio-Rad) and relative quantiﬁcation of miRNA expres-
sion was calculated according to the comparative method
of 2-ΔΔCT.
For detection of other genes, 500 ng of RNA was used
for reverse transcription using TaqMan Reverse Tran-
scription Reagents (Applied Bioisystem, Life Technolo-
gies) and real-time PCR was performed by using
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad)
and the reaction was followed by a melting curve protocol
according to the speciﬁcation of the CFX96 Touch
instrument (Bio-Rad). Primers used were as follows: for
Vimentin R 5′-AGCGAGAGTGGCAGAGGA-3′ and
F 5′-GTTTCCCCTAAACCGCTAGG-3′; for Twist F 5′-
AGCTACGCCTTCTCGGTCT-3′ and R 5′-CCTTCTCT
GGAAACAATGACATC-3′; for CD24 F 5′-TGGATTT
GACATTGCATTTGA-3′ and R 5′-TGGGGGTAGA
TTCTCATTCATC-3′; for alpha-6 integrin (CD49f) F 5′-
TTTGAAGATGGGCCTTATGAA-3′ and R 5′-CCCTG
AGTCCAAAGAAAAACC-3′; for CD44 F 5′-CGGACA
CCATGGACAAGTTT-3′ and R 5′-GAAAGCCTTGCA
GAGGTCAG-3′; for CD44v6 variant F 5′-AGGAACA
GTGGTTTGGCAAC-3′ and R 5′-CGAATGGGAGT
CTTCTCTGG-3′.
All genes expression were normalized relative to human
β-actin with the following primers: ActF 5′-CAGCTC
ACCATGGATGATGATATC-3′ and ActR 5′-AAGCC
GGCCTTGCACAT-3′17. Relative quantiﬁcation of gene
expression was calculated according to the comparative
method of 2-ΔΔCT.
Western blotting
Proteins were extracted with a lysis buffer (TRIS-HCl
50mM pH 8, NaCl 150mM, Triton X-100 1%, NaF 100
mM, EDTA 1mM, MgCl2 1 mM, Glycerol 10%) con-
taining a protease inhibitor cocktail (Sigma-Aldrich) and a
phosphatase inhibitor cocktail (Roche). Equal amounts of
total protein were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and then
transferred to nitrocellulose membranes. The membranes
were blocked with 5% nonfat dry milk in phosphate-
buffered saline (PBS) with 0,1% Tween 20 and incubated
overnight using the following antibodies: anti-β-actin
A5441 (Sigma), anti-Vimentin D21H3 (Cell
Signaling), anti-Zeb1 D80D3 (Cell Signaling) and anti-
Twist 2C1a (Santa Cruz). After washing, membranes were
hybridized with horseradish peroxidase-conjugated sec-
ondary antibodies (rabbit and mouse, Bio-Rad, CA, USA).
Detection was performed with SuperSignal West Dura
extended duration substrate kit (Thermo Scientiﬁc, USA).
FACS analysis
For ﬂow cytometric analysis of CD44, CD24 and
CD44v6 surface markers, 2 × 105 cells per sample, for all
two BCSCs lines tested (BCSC#1 and BCSC#3), were
washed in PBS, resuspended in 100 μl of speciﬁc antibody
diluted in PBS, and incubated for 30min at+ 4 °C. For
BCSCs infected with shmiR-205-5p, construct were used:
APC-H7 mouse anti-human CD44 (cat. no. 560532; clone
G44-26, BD Pharmingen) and BV421 mouse anti-human
CD24 (cat. no. 562789; clone ML5, BD Horizon) evaluating
CD44 and CD24 staining only for GFP-positive cells. For
BCSCs treated for 24 h with 120 pmol LNA, miR-205
inhibitor were used: PE-Cy 7 mouse anti-human CD24 (cat.
no. 561646; clone ML5, BD Pharmingen) and APC-mouse
anti-human CD44 (cat. no. 559942; clone G44-26, BD
Pharmingen). For CD44v6, staining was used: anti-human
CD44v6 (cat. no. BBA13; clone 2F10, mouse IgG1, R&D)
for 30min at+ 4 °C then incubated with anti IgG1 Vioblue
mouse (cat. no. 130-099-084; MACS, Miltenyi Biotec).
ALDH activity was measured following Aldeﬂuor kit
manufacturer’s instructions (Stemcell Technologies) upon
24 h of treatment with 120 pmol LNA miR-205 inhibitor
or a scramble control.
A FACSCantoII ﬂow cytometer, running with FACS-
DiVa software (BD Biosciences), was used for sample
acquisition and analysis.
All antibodies were titrated under assay conditions, in
order to obtain optimal dilutions. Instrument perfor-
mances and data reproducibility were sustained and
checked by using the Cytometer Setup & Tracking
Module (BD Biosciences). In order to assess nonspeciﬁc
ﬂuorescence, ﬂuorescence minus one controls were used.
Compensation was calculated using CompBeads (BD
Biosciences) and single stained samples.
Cell proliferation assay
BCSCs infected with shmiR-205-5p or with an empty
vector were seeded into 24-well plate at 5 × 104 cells/well.
BCSCs treated with miRCURY LNA miR-205-5p inhibitor
were seeded into 24-well plate at 2.5 × 104/well. Viable
cell count was performed with Trypan blue reagent
(Sigma-Aldrich) at the indicated time points. When
indicated, cells were treated with 40 pmol LNA scramble
or miR-205-5p inhibitor (Exiqon).
Invasion assay
BCSCs infected with shmiR-205-5p or treated with 40
pmol LNA-miR-205-5p inhibitor were EGF and FGF
starved overnight. Then 2000 cells were seeded into the
upper chamber of 24-well plate-Transwell 6.5 mm insert,
8 m polycarbonate membrane (Costar, Corning) coated
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with Matrigel (BD). The receiver chamber were ﬁlled with
stem cell culture medium supplemented with 10% Fetal
Bovine Serum (FBS).
After 24 h, non-invaded cells were removed and crystal
violet stain solution was added for 10min. Percentage of
invasion was calculated counting and averaging the
number of stained cells in ﬁve random ﬁelds within each
Transwell insert, dividing this number by the area of the
microscope viewing ﬁeld and then multiplying this
number by the entire area of the Transwell insert. Then,
the total number of cells per insert was normalized by the
number of cells seeded.
Mouse xenograft
NSG mice were purchased from Jackson Laboratory and
bred in the animal facility of CeSI-MeT, G. D’Annunzio
University of Chieti. Animal care and experimental proce-
dures were approved by the Ethics Committee for Animal
Experimentation of the institute according to the Italian law.
Seven weeks old female NSG mice were randomly
divided into two groups (six mice per group) and were
injected unilaterally with 1 × 105 BCSC#3 control and
BCSC#3 sh-mir-205-5p into the fourth mammary fat pad.
Cells were suspended in 200 μl of PBS 1:6 Matrigel (BD
Biosciences).
Tumor growth was monitored twice a week using cali-
pers and animals were sacriﬁced when tumors reached
~1 cm3 of volume. Tumor volume was calculated as 0.5 ×
d12 x d2, where d1 and d2 are the smaller and larger
diameters, respectively. Tumor xenografts and organs
were collected and ﬁxed in 10% neutral-buffered formalin,
parafﬁn embedded, sectioned and stained with hematox-
ylin and eosin (H&E; BioOptica).
In vivo experimental metastasis assay
For experimental lung metastasis assay, BCSC#3 control
and BCSC#3 sh-mir-205-5p cells were resuspended in
PBS and then 2 × 105 cells (in 0.2 mL) were injected via
the lateral tail vein of 7 weeks old female NSG mice (six
mice per group). Mice were killed 35 days after injection
and lungs were harvested and ﬁxed in 10% neutral-
buffered formalin.
To optimize the detection of microscopic metastases
and ensure systematic uniform and random sampling,
lungs were cut transversally, to the trachea, into 2.0 mm
thick parallel slabs with a random position of the ﬁrst cut
in ﬁrst 2 mm of the lung, resulting in 5–8 slabs for lung.
The slabs were then embedded cut surface down and
sections were stained with hematoxylin and eosin. Slides
were independently evaluated by two pathologists.
LNA in vivo treatment
Seven weeks old female NSG mice were randomly
divided into two groups (ﬁve mice per group) and were
injected unilaterally with 1 × 105 BCSC#3 into the fourth
mammary fat pad. The day after cells injection, we treated
mice with 20 mg/kg LNA-i-miR-205-5p or with LNA
scrambled control (Exiqon) intraperitoneally, twice a
week, for 3 weeks. The experiment was conducted for
25 days when mice were sacriﬁced. Tumors and organs
were collected and one part of each organ was preserved
for RNA isolation and the other part was ﬁxed in 10%
neutral-buffered formalin, parafﬁn embedded, sectioned
and stained with H&E for histology analysis.
For experimental metastasis assay, 7 weeks old female
NSG mice were divided into two groups (four mice per
group) and were injected with 2 × 105 BCSC#3 via the
lateral tail vein. The day after injection, mice were intra-
peritoneally treated with 20mg/kg LNA-i-miR-205-5p or
with LNA scrambled control (Exiqon) twice a week for
2 weeks. Mice were sacriﬁced after 30 days and lungs were
collected and sectioned as described above (in vivo
experimental metastasis assay paragraph).
Immunohistochemistry
For immunohistochemistry, slides were deparafﬁnized,
serially rehydrated and, after the appropriate antigen
retrieval procedure, stained with monoclonal mouse anti-
human Ki67 (M7240, Dako), followed by the appropriate
secondary antibody. Immunoreactive antigens were
detected using streptavidin peroxidase (Thermo Scien-
tiﬁc) and the DAB Chromogen System (Dako). After
chromogen incubation, slides were counterstained in
hematoxylin (BioOptica) and images were acquired by
Leica DMRD optical microscope (Leica). The percentage
of KI67-positive cells was evaluated on digital images of
4–6 tumors or lungs per group (4–6 × 200 microscopic
ﬁelds per sample); clear brown nuclei were regarded as
positive cells and the percentage of labeling index (num-
ber of positive cells/total cells × 100) was calculated for
each ﬁeld, by two pathologists, independently.
Statistical analysis
For statistical analysis, GraphPad Prism 6 software was
used, using T-test or ANOVA test with p < 0.05.
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